Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/174830
Title: | Peroxisome Proliferator-Activated Receptor β/δ (PPAR β/δ) as a Potential Therapeutic Target for Dyslipidemia |
Author: | Barroso Fernández, Emma Serrano-Marco, Lucía Salvadó Serra, Laia Palomer Tarridas, Francesc Xavier Vázquez Carrera, Manuel |
Keywords: | Trastorns del metabolisme dels lípids Peroxisomes Lipid metabolism disorders Peroxisomes |
Issue Date: | 3-Feb-2012 |
Publisher: | IntechOpen |
Abstract: | Dyslipidemia is a powerful predictor of cardiovascular disease in patients at high risk (Turner et al., 1998), such as type 2 diabetic patients. Lowering of LDL-C is the prime target for treatment (2002), but even with intensification of statin therapy, a substantial residual cardiovascular risk remains (Barter et al., 2007; Miller et al., 2008; Fruchart et al., 2008; Shepherd et al., 2006). This may partly be due to atherogenic dyslipidemia. This term is commonly used to describe a condition of abnormally elevated plasma triglycerides and low high-density lipoprotein cholesterol (HDL-C), irrespective of the levels of LDL-C (Grundy, 1995). In addition to these key components, increased levels of small, dense LDL-C particles are also present, which in conjunction with the former components conform the also called “lipid triad” (Shepherd et al., 2005). Other abnormalities include accumulation in plasma of triglyceride-rich lipoproteins (TLRs), including chylomicron and very-low-density lipoprotein (VLDL) remnants. This is reflected by elevated plasma concentrations of non- HDL-C and apolipoprotein B-100 (apoB). Postprandially, there is also accumulation in plasma of TLRs and their remnants, as well as qualitative alterations in LDL and HDL particles. Thus, hypertriglyceridemia is associated with a wide spectrum of atherogenic lipoproteins not measured routinely (Taskinen, 2003). The presence of this lipid plasma profile with high triglyceride and low HDL-C levels have been shown to increase the risk of cardiovascular events independent of conventional risk factors (Bansal et al., 2007; Barter et al., 2007; deGoma et al., 2008). In fact, guidelines recommend modifying high triglyceride and low HDL-C as secondary therapeutic targets to provide additional vascular protection (2002). The presence of atherogenic dyslipidemia is seen in almost all patients with triglycerides > 2.2 mmol/l and HDL-C < 1.0 mmol/l, virtually all of whom have type 2 diabetes or abdominal obesity and insulin resistance (Taskinen, 2003)... |
Note: | Reprodució del document publicat a: http://doi.org/10.5772/27647 |
It is part of: | Chapter 11 in: Kelishadi, Roya. 20xx. Dyslipidemia: From Prevention to Treatment. IntechOpen. ISBN: 978-953-307-904-2. DOI: 10.5772/1182. pp. 215-234. |
URI: | http://hdl.handle.net/2445/174830 |
Related resource: | http://doi.org/10.5772/27647 |
Appears in Collections: | Llibres / Capítols de llibre (Farmacologia, Toxicologia i Química Terapèutica) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
261369.pdf | 581.93 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License